The IRay™ system by Oraya Therapeutics is an investigational stereotactic radiosurgical device designed specifically to treat diseases of the eye. [In the U.S., the device does not have an FDA approved IDE.] The single organ focus of Oraya’s technology enables precise delivery of low-energy X-rays to treat wet age-related macular degeneration (AMD).

Evidence suggests that ionizing radiation can close inflammation mediated capillaries and further stop the inflammatory process in conditions such as choroidal neovascularization. Therefore, first clinical indication under study for the IRay system is treatment of wet AMD, in conjunction with the current "gold standard", anti-vascular endothelial growth factor (anti-VEGF) therapy.

Designed to maximize patient comfort and precision, the IRay system utilizes an I-Guide interface, which holds the eye to maintain stability during treatment, while detecting eye motion. A gating system, which automatically shuts down the device in case of misalignment due to patient movement, is also featured. Because the radiation delivered is low-voltage, comparable to a chest or dental X-ray, and the system includes shielding to protect the patient and operator, the IRay is usable in a typical ophthalmology office setting. The entire patient treatment process requires only a topical anesthetic, and patients are able to leave the office within 15 to 20 minutes of receiving treatment.

Contact us for more information on IRay clinical trials.